Interpace Biosciences enters $7.5M revolving credit facility with Comerica Bank

INTERPACE BIOSCIENCES, INC.

Credit facility of up to $7.5M, matures September 30, 2023, secured by substantially all assets.
Advances based on 80% of eligible accounts receivable plus $2M non-formula availability stepping down $250K/quarter.
Interest rate equals prime plus 0.50% (prime is greater of Comerica's rate or daily LIBOR + 2.5%).
Existing $7.5M bridge loans from private equity investors subordinated to Comerica's first-priority lien.
Proceeds for working capital and general corporate purposes; unused facility fee of 0.25% per annum.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.